Effects of interferon-beta therapy on elements in the antiviral immune response towards the human herpesviruses EBV, HSV, and VZV, and to the human endogenous retroviruses HERV-H and HERV-W in multiple sclerosis

Journal of Neuroimmunology

Volumn 249, Issue 1-2, 2012, Pages 105-108

  Petersen, Thor ^a   Møller Larsen, Anné ^b   Ellermann Eriksen, Svend ^a   Thiel, Steffen ^b   Christensen, Tove ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Complement activation; EBV, HSV, VZV, CMV; HERV H; HERV W; Interferon beta; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; EPSTEIN BARR VIRUS ANTIGEN 1; INTERFERON BETA SERINE; MANNAN BINDING LECTIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 3; PROTEIN HERV H; PROTEIN HERV W; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SEROLOGY; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS;

ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHICKENPOX; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; ENDOGENOUS RETROVIRUSES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SIMPLEXVIRUS; VIRUS DISEASES; YOUNG ADULT;

EID: 84863457070     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.04.013     Document Type: Article

References (37)

1. Antony J.M., Van Marle G., Opii W., Butterfield D.A., Mallet F., Yong V.W., Wallace J.L., Deacon R.M., Warren K., Power C. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat. Neurosci. 2004, 7:1088-1095.
2. Ascherio A., Munger K.L. Epstein-Barr virus infection and multiple sclerosis: a review. J. Neuroimmune Pharmacol. 2010, 5:271-277.
3. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004, 55:458-468.
4. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R., Stanton G.J., Hughes T.K. The interferons. Mechanisms of action and clinical applications. JAMA 1991, 266:1375-1383.
5. Burgoon M.P., Cohrs R.J., Bennett J.L., Anderson S.W., Ritchie A.M., Cepok S., Hemmer B., Gilden D., Owens G.P. Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann. Neurol. 2009, 65:474-479.
6. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev. Med. Virol. 2005, 15:179-211.
7. Christensen T. Human herpesviruses and MS. Int. MS J. 2007, 14:41-47.
8. Christensen T. HERVs in neuropathogenesis. J. Neuroimmune Pharmacol. 2010, 5:326-335.
9. Christensen T., Dissing Sørensen P., Hansen H.J., Møller-Larsen A. Antibodies against a human endogenous retrovirus and the preponderance of env splice variants in multiple sclerosis patients. Mult. Scler. 2003, 9:6-15.
10. Christensen T., Petersen T., Thiel S., Brudek T., Ellermann-Eriksen E., Møller-Larsen A. Gene-environment interactions in multiple sclerosis: innate and adaptive immune responses to human endogenous retrovirus and herpes virus antigens and the lectin complement activation pathway. J. Neuroimmunol. 2007, 183:175-188.
11. Christiansen O.B., Kilpatrick D.C., Souter V., Varming K., Thiel S., Jensenius J.C. Mannose-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand. J. Immunol. 1999, 49:193-196.
12. Comabella M., Kakalacheva K., Río J., Münz C., Montalban X., Lünemann J.D. EBV-specific immune responses in patients with multiple sclerosis responding to IFN {beta} therapy. Mult. Scler. 2011, 10.1177/1352458511426816.
13. DeLorenze G.N., Munger K.L., Lennette E.T., Orentreich N., Vogelman J.H., Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 2006, 63:839-844.
14. Farrell R.A., Antony D., Wall G.R., Clark D.A., Fisniku L., Swanton J., Khaleeli Z., Schmierer K., Miller D.H., Giovannoni G. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009, 73:32-38.
15. Fernald G.H., Knott S., Pachner A., Caillier S.J., Narayan K., Oksenberg J.R., Mousavi P., Baranzini S.E. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J. Immunol. 2007, 178:5076-5085.
16. Giovannoni G. Epstein-Barr virus and MS. Int. MS J. 2011, 17:44-49.
17. Hafler D. Multiple sclerosis. J. Clin. Invest. 2004, 113:788-794.
18. Hogancamp W.E., Rodriguez M., Weinshenker B.G. The epidemiology of multiple 1997.
19. Ingram G., Bugert J.J., Loveless S., Robertson N.P. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur. J. Neurol. 2010, 17:1386-1389.
20. Kang J.H., Sheu J.J., Kao S., Lin H. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. J. Infect. Dis. 2011, 204:188-192.
21. Koch-Henriksen N., Sørensen P.S., Christensen T., Frederiksen J., Ravnborg M., Jensen K., Heltberg A., Kristensen O., Stenager E., Petersen T., Hansen T. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006, 66:1056-1060. Danish Multiple Sclerosis Group.
22. Kornek B., Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 2003, 6:321-326.
23. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
24. Lünemann J.D., Tintoré M., Messmer B., Strowig T., Rovira A., Perkal H., Caballero E., Münz C., Montalban X., Comabella M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 2010, 67:159-169.
25. Moller-Kristensen M., Jensenius J.C., Jensen L., Thielens N., Rossi V., Arlaud G., Thiel S. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J. Immunol. Methods 2003, 282:159-167.
26. Munger K.L., Levin L.I., O'Reilly E.J., Falk K.I., Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 2011, 17:1185-1193.
27. Petersen T., Møller-Larsen A., Thiel S., Brudek T., Hansen T.K., Christensen T. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis. J. Neuroimmunol. 2009, 215:208-216.
28. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
29. Simmons A. Herpesvirus and multiple sclerosis. Herpes 2001, 8:60-63.
30. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., Kristensen O., Petersen T., Rasmussen S., Ravnborg M., Stenager E., Koch-Henriksen N. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003, 362:1184-1191. Danish Multiple Sclerosis Study Group.
31. Sotelo J., Ordoñez G., Pineda B. Varicella-zoster virus at relapses of multiple sclerosis. J. Neurol. 2007, 254:493-500.
32. Sotelo J., Martinez-Palomo A., Ordoñez G., Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. Ann. Neurol. 2008, 63:303-311.
33. Thiel S., Holmvad S.H., Dahl M., Jensenius J.C. An assay for mannan-binding lectin (MBL) associated serine protease 3, MASP-3. Mol. Immunol. 2006, 43:122-191.
34. Thiel S., Steffensen R., Christensen I.J., Ip W.K., Lau Y.L., Reason I.J., Eiberg H., Gadjeva M., Ruseva M., Jensenius J.C. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun. 2007, 8:154-163.
35. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 2006, 25:343-348.
36. Weinstock-Guttman B., Ramanathan M., Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert. Opin. Biol. Ther. 2008, 8:1435-1447.
37. Ytting H., Christensen I.J., Thiel S., Jensenius J.C., Svendsen M.N., Nielsen L., Lottenburger T., Nielsen H.J. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age, gender and physical exercise. Scand. J. Immunol. 2007, 66:458-464.